H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $267. The company’s shares closed yesterday at $110.94.
Chattopadhyay said:
“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.42, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.4%, and tax rate of 15% beginning in FY 2024.”
According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -8.1% and a 36.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $206.60 average price target, an 86.2% upside from current levels. In a report issued on December 28, BTIG also maintained a Buy rating on the stock with a $190 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $50.68. Currently, Sarepta Therapeutics has an average volume of 1.07M.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 6,667 shares for a total of $936,714.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
